Skip To Main Content



Medical Information Letters

The Genentech resources below are patient-friendly summaries of data related to emicizumab and safety topics. These patient-friendly summaries include studies with the strongest and most relevant data and are provided only for educational purposes. You are encouraged to discuss any questions you have about your condition and any current or potential treatments with your healthcare provider.

HEMLIBRA and Thrombotic Microangiopathy and Blood Clot (Thrombotic Event) Side Effects

Side Effects With HEMLIBRA


Select scientific data presentations with the strongest and most relevant data are provided below.

Evaluation of the Safety of Emicizumab Prophylaxis in Persons With Hemophilia A: An Updated Summary of Thrombotic Events and Thrombotic Microangiopathies

Howard M, McKinley D, Sanabria F, et al. Presented at the ASH Scientific Meeting; December 11-14, 2021.

Summary of Thrombotic Events or Thrombotic Microangiopathy Events in Persons Taking Emicizumab

Lee L, Moreno K, Kuebler P, et al. Presented at the Virtual NHF Scientific Meeting; August 1-8, 2020.

Safety and Efficacy of Long-Term Emicizumab Prophylaxis in Hemophilia A With Factor VIII Inhibitors: A Phase 3b, Multicenter, Single-Arm Study (STASEY)

Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. Res Pract Thromb Haemost 2022;6:e12837.

Final Analysis of the STASEY trial: A Single-arm, Multicenter, Open-label, Phase III Clinical Trial Evaluating the Safety and Tolerability of Emicizumab Prophylaxis in Persons with Hemophilia A with Factor VIII Inhibitors

Jiménez-Yuste V, Peyvandi, F, Klamroth R, et al. Presented at the Virtual ISTH Scientific Meeting; July 17-21, 2021.

Archived data reports on thrombotic microangiopathy, serious thrombotic events, and fatalities were last updated June 30, 2020. Please note that there will be no further updates of these archived materials.